

# CD8<sup>+</sup> Cytotoxic T Lymphocyte Responses and Viral Epitope Escape in Acute HIV-1 Infection

Joseph Kim,<sup>1</sup> Justin De La Cruz,<sup>1</sup> Karen Lam,<sup>2</sup> Hwee Ng,<sup>1</sup> Eric S. Daar,<sup>3</sup>  
Arumugam Balamurugan,<sup>1</sup> and Otto O. Yang<sup>1,2,4</sup>

## Abstract

Epitope escape from HIV-1-targeted CD8<sup>+</sup> cytotoxic T lymphocyte (CTL) responses occurs rapidly after acute infection and contributes to the eventual failure of effective immune control of HIV-1 infection. Because the early CTL response is key in determining HIV-1 disease outcome, studying the process of epitope escape is crucial for understanding what leads to failure of immune control in acute HIV-1 infection and will provide important implications for HIV-1 vaccine design. HIV-1-specific CD8<sup>+</sup> T lymphocyte responses against viral epitopes were mapped in six acutely infected individuals, and the magnitudes of these responses were measured longitudinally during acute infection. The evolution of autologous circulating viral epitopes was determined in four of these subjects. In-depth testing of CD8<sup>+</sup> T lymphocyte responses against index and all autologous-detected variant epitopes was performed in one subject. Among the four individuals examined, 10 of a total of 35 CD8<sup>+</sup> T cell responses within Gag, Pol, and Nef showed evidence of epitope escape. CTL responses with viral epitope variant evolution were shown in one subject, and this evolution occurred with and without measurable CTL responses against epitope variants. These results demonstrate a dynamic period of viral epitope evolution in early HIV-1 infection due to CD8<sup>+</sup> CTL response pressure.

**Keywords:** HIV-1, T lymphocyte immunity, escape from immune responses, cell-mediated immunity

## Introduction

CD8<sup>+</sup> CYTOTOXIC T lymphocytes (CTLs) are an important component of the immune response during HIV-1 infection (6,21,8,41,15,33). Mathematical modeling of early infection suggests that the CTL response significantly affects the initial reduction in viral load (12). The specific CTL responses that develop in acute infection are associated with an infected individual's viral set point (35), a measure that is predictive of disease outcome (27). In addition, the absolute magnitude and rate of peaking of the CD8<sup>+</sup> T lymphocyte response have been shown to correspond to a lower viral set point (28), and rapid escape from immunodominant CD8<sup>+</sup> T lymphocyte responses in acute infection is associated with a halt in viral load decline (13).

However, CTL-mediated immunity does not typically lead to containment or eradication of HIV-1 infection. The reason for this failure of CTL-mediated immunity is multifactorial (34,37,10) and involves the evasion of CTL re-

sponses by viral epitope escape (30). Understanding what factors may decrease the likelihood of viral escape, particularly in early HIV-1 infection, would help explain why the CTL immune response fails to lead to successful immunity and would also help advance the development of a successful vaccine (36).

Viral epitope escape of the CTL response occurs as a result of the high mutation rate of the HIV-1 genome during viral replication, estimated to be equivalent to every single- or double-point mutation of the HIV-1 genome sequence to be produced every day in the viral pool of an infected individual (9). Although mutations may lead to significant effects on viral protein structure and function, resulting in a fitness cost to certain variant species (24), sufficient variations in viral sequences occur to produce epitope escape of CTL responses (26). Epitope escape has been shown to occur readily in early HIV-1 infection models (3), and as early as 16 days after the onset of symptoms of primary HIV-1 infection (7) in humans.

<sup>1</sup>Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California.

<sup>2</sup>Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, California.

<sup>3</sup>Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, California.

<sup>4</sup>AIDS Healthcare Foundation, Los Angeles, California.

Escape by reduced recognition of the T cell receptor (TCR) is limited by CTL promiscuity, or the ability of CTL responses to recognize and target variant epitopes. Given the stochastic development of the TCR, each CTL clone has distinct promiscuity, such that each clone can target a unique set of epitope variants (42). A CTL response against a particular epitope can also involve more than one T cell clone, and the number of clones comprising a response shared between individuals can vary (5,40). The sum total of all CTL clones specific to a given epitope represents the clonal breadth of a CTL response to a particular epitope. Because the number of variant epitopes targeted would be greater, CTL responses with larger breadth may better restrict viral escape. Escape may also be contained by the formation of new CTL responses with distinct clonal repertoires developing against variant epitopes selected under CTL immune pressure (4).

Studying the viral epitope evolution in early infection and investigating the effect of CTL clonal breadth and new CTL response development against these epitopes will add to the understanding of what constitutes a more robust CTL response, aiding in HIV-1 vaccine design and development. In this exploratory study, we systematically identified CD8<sup>+</sup> T lymphocyte responses during acute infection and correlated the progression of these immune responses to the evolution of viral epitope variants. We sought to expand on prior studies by tracking the magnitude of CTL responses against targeted epitopes as well as detected autologous variant epitopes to explore how clonal breadth may influence the development of epitope escape and give further insights into the dynamics of this process. Our results show a detailed picture of the CD8<sup>+</sup> CTL response during a period of active viral evolution in acute HIV-1 infection.

## Materials and Methods

### Study subjects

Six acutely infected individuals were studied, each with detectable level of HIV-1 virus in blood and negative detuned ELISA and/or Western blot at the time of enrollment. Peripheral blood mononuclear cells (PBMCs) and plasma were collected at multiple time points from each subject beginning from the time of enrollment up to 13 weeks afterward. HLA serologic equivalent testing of subjects was performed with sequence-specific oligonucleotide hybridization.

### Cell culture

All cell culture utilized medium consisting of RPMI 1640 (Sigma) supplemented with 10% heat-inactivated fetal calf serum, 10 mM N-2-hydroxyethylpiperazine-N9-2-110 ethanesulfonic acid, and 2 mM glutamine, unless otherwise noted.

### Nonspecific expansion of CD8<sup>+</sup> T lymphocytes from PBMC

CD8<sup>+</sup> T lymphocytes were nonspecifically expanded from PBMC in culture containing 50 U/mL of recombinant human interleukin-2 (NIH AIDS Reference and Reagent Repository) and CD3:CD4 bispecific antibody (39) for 2 weeks, consistently resulting in CD3<sup>+</sup> lymphocyte populations that were >90% CD8<sup>+</sup>.

### Detection of CTL responses with ELISpot

Ninety-six-well nitrocellulose filter plates (Millipore, Burlington, MA) were coated with monoclonal anti-IFN-gamma antibody (Pharmingen; BD Biosciences, San Diego, CA) and plated with up to  $2 \times 10^5$  expanded CD8<sup>+</sup> T lymphocytes per well in medium. Cells were treated with a library of consecutive 15-mer HIV-1 peptides overlapping by 11 amino acids and spanning all HIV-1 Clade B consensus proteins (NIH AIDS Research and Reference Reagent Repository) or specific minimal peptide epitopes. Minimal peptide epitopes were selected based on previously known HLA class I antigens or by predicting the most likely minimal epitope within a positively screened 15-mer peptide using the online programs SYFPEITHI Epitope prediction (31) and Bioinformatics and Molecular Analysis Section (Bimas) (29). Cells were treated with peptides at a concentration of 5 µg/mL. Each plate also contained four negative control wells without peptide stimulation, and a positive control well treated with 1 mg/mL phytohemagglutinin (PHA). After incubation for 12–16 h, cells were stained with a biotinylated second IFN-gamma-specific antibody labeled with streptavidin peroxidase. Each well was then treated with streptavidin peroxidase and developed with a peroxidase color reagent. Spots that formed on well filters representing individual IFN-gamma-secreting CD8<sup>+</sup> T lymphocytes were counted as spot-forming units (SFU) with an automated counter (Cellular Technologies Limited, Cleveland, OH) and confirmed manually. Positive responses were defined as having at least 60 SFU per million cells and more than the mean plus three times the standard deviation of the negative wells (14). Peptides were screened with pools of 12–16, and individual CTL responses were identified with individual peptides.

### Detection of autologous viral variants within Gag-Pol and Nef sequences

Creation of an NL4-3 ΔGag-Pol cloning vector. The p83-2 plasmid containing the 5' genomic portion of NL4-3 (1) served as the starting template for the construction of a target vector for rapid cloning of primary Gag-Pol sequences into the NL4-3 backbone. First, site-directed mutagenesis (QuikChangeII XL; Agilent, Westlake Village, CA) was performed to change nucleotides 781–786 into an *Stu*I site (AGG<sup>^</sup>CCT). Second, nucleotides 5,044–5,049 were mutagenized to contain an *Hpa*I site (GTT<sup>^</sup>AAC), which also created a premature stop codon to eliminate virus production from plasmid without the desired Gag-Pol replacement. This formed the p83-2ΔGag-Pol vector. In addition, a whole genome version was constructed by creating an *Nru*I site at the junction of the HIV-1 insert and the plasmid backbone of p83-2ΔGag-Pol. After cutting with *Nru*I and *Eco*RI (New England Biolabs, Ipswich, MA), the resulting HIV-1 fragment was ligated into either p83-10/HSA or p83-10/HSA-HA plasmids containing the 3' end of the HIV-1 genome with reporter genes in the Nef locus as previously described (2). This formed the pNL4-3/HSAΔGag-Pol and pNL4-3/HSA-HAΔGag-Pol whole genome plasmids. All modifications were confirmed by sequencing.

HIV-1 Gag-Pol amplification and cloning into NL4-3. Viral RNA was isolated from plasma using the QIAamp UltraSens

viral isolation kit (Qiagen, Germany). Viral RNA was then reverse transcribed and the Gag-Pol region of the HIV-1 genome was amplified using multiple primers spanning these regions. Hemi-nested PCR was performed using KOD hifidelity DNA polymerase (EMD, Billerica, MA). The first PCR used primers 737F and AGPolRnst, and the second PCR used primers F2nst and AGPolRnst (Supplementary Table S1; Supplementary Data are available online at [www.liebertpub.com/vim](http://www.liebertpub.com/vim)). Both PCRs were conducted under the following conditions: 20 sec at 95°C, 40 cycles of 95°C for 20 sec plus 62°C for 30 sec plus 70°C for 2.5 min, followed by a final extension at 70°C for 10 min. The second PCR primers included overhang sequences that corresponded to the HIV-1 sequences flanking the *StuI*-*HpaI* sites in the  $\Delta$ Gag-Pol vectors. Each primary Gag-Pol PCR product (in bulk, uncloned) and an appropriate  $\Delta$ Gag-Pol vector after excision of the *StuI*-*HpaI* restriction fragment (New England Biolabs, Ipswich, MA) were combined using the In-Fusion kit (Clontech, Mountain View, CA) to create NL4-3 genomic quasiespecies containing subject-derived Gag-Pol.

**Full-length Gag-Pol sequencing and analysis.** Nine or more full-length Gag-Pol clones per time point were isolated per subject by picking bacterial colonies after transformation of the final plasmid constructs. Full-length Gag-Pol DNA sequencing was completed with 10 primers (Supplementary Table S1) using the Big Dye 3.1 sequence terminator kit (Applied Biosystems, Carlsbad, CA) on an AB3130 genetic analyzer and edited with ChromasLite. Edited sequences from each clone were assembled into the full-length

Gag-Pol sequence, translated, and aligned to the Los Alamos HIV Sequence Database 2010 clade B consensus sequence, manually adjusted using BioEdit, and analyzed for fixed amino acid changes.


The protocol for Nef sequences is described in De La Cruz *et al.* (11). Detection of autologous viral sequences was not performed on subjects 3 and 6 due to unavailability of samples.

The materials, methods, and study design were reviewed and approved by the University of California–Los Angeles Institutional Review Boards (IRBs) to ensure protection of human subjects.


## Results

Each of the six subjects demonstrated detectable viral blood levels and had negative detuned ELISA and/or Western blot tests at the day of enrollment (day 0). The HLA profiles of subjects are shown in Supplementary Table S2. PBMC and plasma samples were obtained spanning a time frame of up to 13 weeks. The plasma viral load and CD4 T cell counts during the testing time period for each subject are shown in Figure 1.


ELISpot mapping in these subjects revealed 54 distinct responses against screening 15-mers (after accounting for overlaps in amino acid sequences) and 32 distinct responses against previously known epitope antigens. Fourteen of the previously known epitope antigens were located within screening 15-mer peptide sequences, representing the corresponding targeted minimal epitope. Five more minimal epitope antigens were identified within Gag, Pol, and Nef



**FIG. 1.** Viral blood levels and CD4 T cell counts of the six subjects measured at several time points over the course of the sampling period. Black lines represent viral load (in Log [copies/mL]) of different subjects, and dotted color lines represent CD4 T cell counts (in cells/mL) of different subjects; lines corresponding to number of subjects are shown in the legend.



**FIG. 2** (A) (*top*) Magnitude of the CD8<sup>+</sup> T cell response determined by ELISpot in subject 1 from stimulation with the 15-mer peptide WASQIYAGIKVKQLC (Pol 421–435), measured in SFU per million cells; CD8<sup>+</sup> T cell responses also determined for targeted minimal epitope variants of circulating viruses (QIYAGIKVK and QIYAGIKIK) on day 77. (*bottom*) Frequencies of each detected variant of the targeted peptide are noted in the table; *dashes* represent similarity to index sequence. (B) (*top*) Magnitude of the CD8<sup>+</sup> T cell response in subject 5 determined by ELISpot from stimulation with the overlapping 15-mer peptides IYSQKRQDILDWVY (Nef 101–115) and KRQDILDWVYHTQG (Nef 105–119), in SFU per million cells; CD8<sup>+</sup> T cell responses also determined for targeted minimal epitope variants of circulating viruses (KRQDILDWVY, KRQDILDWVY, ERQDILDWVY, and RRQDILDWVY) on day 0. (*bottom*) Frequencies of each detected variant of the targeted peptide are noted in the table; *dashes* represent similarity to index sequence. \*Represents a peptide that was tested in separate ELISpot assays. SFU, spot-forming units; ND, not done.



**FIG. 3.** Location of each targeted peptide antigen (*arrows*) for all six subjects in the nucleotide sequence of HIV-1 (*x*-axis); colors correspond to the specific protein sequence map describing which protein each target peptide is located.

by testing the SYFPEITHI or Bimas-predicted minimal epitopes within the remaining positively screened Gag, Pol, and Nef 15-mer peptides (marked in red in Supplementary Fig. S1). Figure 2A (top) shows a representative CTL response against a peptide (WASQIYAGIKVKQLC) in subject 1 measured with five sampling points over a span of 77 days.

The location of each final determined peptide antigen for all six subjects is shown in Figure 3, with the number of

responses within each HIV-1 protein given in Table 1. Each epitope region was defined as a positively screened 15-mer peptide, an 8–11 amino acid sequence overlap between two positively screened 15-mer peptides, or a determined minimal epitope. The number of responses varied between each individual from 4 to 26, and the majority were directed at targets within Gag-Pol, Nef, and Env.

For each PBMC sample in subjects 1, 2, 4, and 5, the corresponding plasma was isolated and autologous viral

**TABLE 1.** NUMBER OF RESPONSES WITHIN EACH HIV-1 PROTEIN IDENTIFIED FOR EACH SUBJECT

	Gag	Pol	Nef	Env	Vif	Vpr	Rev	Total	Number of responses escaped		
									Gag	Pol	Nef
1	1	1		2				4		1	
2	2		3	5				10			2
3	1	5		2				8	ND	ND	ND
4	7	5	5	6	1	1	1	26	2		4
5	1	3	1	7	1	2	1	16			1
6	2	1	3	1	1			8	ND	ND	ND

ND, not done.

epitope variants within Gag, Pol and Nef-targeted epitopes were sequenced. Sequences were obtained at time points spanning at least 70 days (Supplementary Fig. S1). The frequencies of each detected variant were determined as shown for the representative CTL response against WASQIYAGIKVKQLC in Figure 2A (bottom).

In subjects 1, 2, 4, and 5, 10 of the 29 total responses within Gag, Pol, and Nef showed a decrease in the frequency of the most abundant initial epitope (index epitopes) over time (Table 1 and Supplementary Fig. S1), indicating that CTL pressure could be leading to epitope escape (instances where only one variant epitope sequence was noted at the last time point were excluded from this count). For example, in subject 1, there was a clear evolution of the index epitope QIYAGIKVK to the variant QIYAGIKIK, which becomes the only epitope detected at the final time point (Fig. 2A bottom). Equivalent CTL responses to both index and variant epitopes were detectable at the final time point. In subject 5, there was a decrease in frequency of the index epitope KRQDILDLWVY and the appearance of multiple different variants at the last two time points (Fig. 2B bottom). Interestingly, there were detectable CTL responses against these later variants on day 0 along with relatively strong responses against the index epitope and variant KRQDILDLWIY (Fig. 2B top).

To create a comprehensive examination into epitope evolution and its relationship to CTL pressure against the index and all variant epitopes, ELISpot testing was repeated on all detected minimal viral epitope sequences in subject 4 (sample availability limited this analysis to only this subject). Twelve responses were tested that revealed several different scenarios (Fig. 4).

#### *Responses where no variants were detected*

In the response against minimal epitope PLTFGWYCYKL (Fig. 4A), no epitope variants were detected at any time point. Although the magnitude of the CTL response decreased, it was still detectable against the epitope until the last time point measured.

#### *Instances where detection of the initial positive screening response was not replicated upon testing of variants*

In CTL responses against the minimal epitopes ILKEPVHGV (Fig. 4B), ALVEICTEM (Fig. 4C), TLNAWVKVV (Fig. 4D), LVGPTPVNI (Fig. 4E), and FLGKIWPSHK (Fig. 4F), no measurable CTL responses against the initially screened index epitopes were detected during testing of epitope variants. In four of these responses, any variant epitopes found were present in low frequencies (only one out of all cloned sequences), and with the exception of the response against TLNAWVKVV, no variant was detected at more than one time point.

#### *Instances where index CTL response was replicated, but no clear pattern of epitope variants in relation to CTL responses noted*

In the response against the minimal epitope IYQYMDDLIV (Fig. 4G), one variant was seen on day 0 at low frequency. A response against the variant, IYQYLDLIV, was seen on days 61 and 89, whereas the CTL response against the index

epitope was only detected on day 89. In the response against SLYNTVATL (Fig. 4H), the CTL response against the index epitope was only noted at the last time point on day 89. A response against the variant SLYNTVPTL was detected at day 0; however, this was before the circulating variant was found.

#### *Instances with persistent CTL responses against index epitopes but no responses seen against epitope variants*

In CTL responses against the minimal epitopes EIYKRWII (Fig. 4I), FLKEKGGL (Fig. 4J), and AFHHVAREL (Fig. 4K), responses against the index epitopes could be confirmed, but no consistent CTL responses against variant epitopes were seen. In the case of EIYKRWII, the detected variant, EIYKRGII, was only noted at low frequency on days 0 and 12. In the response against the epitope AFHHVAREL, there was a clear increase in viral epitope diversity with corresponding decrease in frequency of the index epitope over time. Although the CTL response against the index epitope, AFHHVAREL, was measured in a separate ELISpot assay, it was shown to persist beginning on day 21. A response was detected at day 0 against the variant epitope AFHHMAREL; however, this was before the detection of this circulating variant on day 61. In the response against FLKEKGGL, the persistently targeted epitope was detected only at day 0 and at a lower frequency as the variant FLKEEGGL. However, there was a clear shift in variant species away from FLKEKGGL to the variants FLKEEGGL and FLKEQGGL. Therefore, despite not being the most abundant initially, the epitope FLKEKGGL most likely represents the index epitope given these dynamics.

#### *Instances where CTL responses were seen against variants that persisted*


One CTL response was noted against two variants at equal frequency on day 0, KRQEILDLWIY and KRQEILDLWIH (Fig. 4L). These variants were no longer detected by day 61, and by day 89, only two other variants remained, KRQEILDLWMY and KRQDILDLWIY. These final variants were targeted by CTL responses at all time points, with the highest frequency variant, KRQEILDLWMY, having the largest magnitude response on day 89.

## Discussion

The level of virus decreased and stabilized in most subjects, indicating that their clinical time frame reflects Fiebig stage IV or V. The fall and then rebound of viral load seen in subject 4 is not typical of early infection.

Consistent with prior findings (7,13,23), evidence of epitope escape in acute infection was seen in multiple CTL responses, and the number of targeted epitopes varied between individuals (12,16,22). Similar to results from a study by Liu *et al.* (22) that examined viral CTL-targeted epitope dynamics in acute infection, a greater proportion of escape was seen in Nef-targeted epitopes within the 100 days following Fiebig stage I/II. However, our results differ in that a larger proportion of targeted epitopes were seen in Pol (21% of the total in this study vs. 3% in Liu *et al.*), and a smaller rate of escape occurred for epitopes within Gag, Pol, and Nef proteins within this time period (34% in this study vs. 53% in Liu *et al.*) despite a stricter definition of escape being





**FIG. 4.** (A– L) (top) Magnitude of CD8<sup>+</sup> T cell responses in subject 4 determined by ELISpot from stimulation with all determined minimal epitopes as well as all detected viral variant epitopes at more than one time point, in spot-forming units (SFU) per million cells. (bottom) Frequencies of each detected variant of the targeted peptide are noted in the table; *dashes* represent similarity to index sequence. \*Represents a peptide that was tested in separate ELISpot assays. ND, not done.




FIG. 4. (Continued).






FIG. 4. (Continued).

utilized (<50% of transmitted/founder viral sequence detected). These inconsistencies are certain to be influenced by differences in methodologies, as the Single Genome Amplification utilized in Liu *et al.* would provide greater sensitivity for detecting evolution in viral sequences. However, contrary to the suggestion in Liu *et al.*, the detection of CTL responses against peptide epitopes in Pol would suggest that this conserved region can be considered in determining targets for vaccine design.

In the majority of these escaped responses (8 of 10), the initial CTL response against the index epitope persisted during this fall in frequency. One possibility for this is that although the level of index epitope virus decreased, some still persists to provide enough antigenic stimulation to maintain the CTL response (Fig. 4K). Another explanation would be that the initial index CTL response possesses promiscuity against evolving viral variants. These viral variants could potentially have a replicative advantage over the index epitope virus, or as a result of original antigenic sin (20), the index CTL response may be suboptimal against the variant epitopes and at the same time interfere with the maturation of naive CTL clones that would better target variant epitopes (Fig. 4L). Finally, it is possible that the index CTL response would continue to decay if trended for a longer period of time (Fig. 4J).

For the epitope KRQDILDWVY in subject 5 (Fig. 2B) and the epitopes KRQEILDLWIY and KRQEILDLWIH in sub-

ject 4 (Fig. 4L), CTL responses against variant epitopes that subsequently developed were present at day 0, before their detection. This may indicate promiscuity of the CTL response against the index epitope rather than the development of a new response. The evolution of the circulating variants away from the index epitope may, therefore, reflect other factors that lead to a competitive advantage of viral species with these epitope sequences such as altered viral epitope processing or presentation, or improved viral replication. Although these responses in two different individuals are against the same HLA-Cw restricted epitope antigen, because the variant species noted in each subject are not similar, it is more likely that the CTL responses between these two individuals are distinct.

Because several positively screened CTL responses in subject 4 that did not show evidence of epitope escape could not be replicated during variant epitope testing (Fig. 4B–F), it is possible that this proportion of detected responses reflect a falsely positive result. This could explain the overall greater proportion of invariant targeted epitopes than previously noted (22). However, at least some of these instances may be a result of constraints placed on escape by viral fitness costs (Fig. 4I).

In studies of early HIV-1 infection, a greater response breadth, or number of HIV-1-specific CTL responses, was associated with less likelihood of escape from T cell




FIG. 4. (Continued).

responses within one studied individual (22). Mathematical modeling of the effect on CTL response breadth in HIV-1 infection suggested that a broader response would lead to less viral escape in early infection from a combined effect of all CTL responses in killing infected cells, balancing out the production of infected cells (38). It was also shown that increasing CTL response breadth corresponded to lower viral load in HIV-1-infected individuals; however, this association was only noted for Gag-specific antigen responses (19). Thus, although response breadth likely affects immune control in viral infection, there are other factors, such as the conservation of targeted antigen targets, that will possibly affect this relationship. Among our subjects, there was no clear association with the number of CTL responses and lower viral set point (determined by the last viral blood-level measurement in each subject). Larger number of individuals must be studied to make more definitive conclusions about the relationship between response breadth and viral set point and propensity for escape.

None of the instances of possible epitope escape in the setting of a persistent CTL index response in subject 4 were noted to have the development of a new CTL response against

epitope variants. Because CD4<sup>+</sup> T cells have been shown to be necessary to sustain (25) and promote formation of new CTL responses in chronic viral infections (18), the formation of new responses against HIV-1 epitopes may be impaired by the lack of CD4<sup>+</sup> T cell help. Indeed, viremic control in HIV-1 infection has been associated with the presence of CD4<sup>+</sup> T cell-dependent proliferative responses to viral antigens (17,32). The absolute CD4 count ranged from 419 to 538 cells/mm<sup>3</sup> in this subject during the time of testing; however, functional testing of these cells was not performed. In addition, new CTL responses may also be compromised by the process of original antigenic sin (20). Although the magnitude of the response to epitope variants of the index epitopes KRQEILDLWIH and KRQEILDLWIY in subject 4 (Fig. 4J) was relatively strong, it is possible that these responses did not produce effective *in vivo* control of viral replication and potentially limited the formation of new CTL responses to developing variants.

Subject 4 plasma viral levels demonstrated an atypical rise after a nadir at day 12, and remained elevated throughout the time period tested. This likely reflects a poor overall CTL response not just related to escape of but also CD4<sup>+</sup> and CD8<sup>+</sup> T cell function.

In this study, we successfully performed an in-depth analysis of the CTL-targeted viral epitopes in six acutely HIV-1-infected individuals, and when possible, we determined the targeted minimal epitopes. The evolution of these targeted epitopes was tracked during early infection, and in one subject, we were able to comprehensively examine the relationship between these changes in viral variant epitopes and the magnitude of CTL responses against them. Our results demonstrate a period of both dynamic viral epitope variation and epitope stability under CTL pressure spanning the period of acute HIV-1 infection. This promising approach can be applied to future studies involving larger cohorts of acutely infected individuals to derive further insight into how clonal breadth, the development of new CTL responses, and other factors such as the CD4<sup>+</sup> T cell response influence epitope escape.

### Acknowledgments

This work was performed with grant support from the NIAID (grant numbers A1043203 and A1089398) and the AIDS Healthcare Foundation. Recombinant human interleukin-2 was provided by the NIH AIDS Reagent Repository. The University of California AIDS Institute CFAR grant provided supportive infrastructure for this project.

### Author Disclosure Statement

The authors have no conflicts of interest.

### References

- Ali A, Jamieson BD, and Yang OO. Half-genome human immunodeficiency virus type 1 constructs for rapid production of reporter viruses. *J Virol Methods* 2003;110:137–142.
- Ali A, and Yang OO. A novel small reporter gene and HIV-1 fitness assay. *J Virol Methods* 2006;133:41–47.
- Allen TM. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. *Nature* 2000;407:386–390.
- Allen TM, Yu XG, Kalife ET, *et al.* De novo generation of escape variant-specific CD8<sup>+</sup> T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection. *J Virol* 2005;79:12952–12960.
- Balamurugan A, Ng HL, and Yang OO. Rapid T cell receptor delineation reveals clonal expansion limitation of the magnitude of the HIV-1-specific CD8<sup>+</sup> T cell response. *J Immunol* 2010;185:5935–5942.
- Borrow P, Lewicki H, Hahn BH, Shaw GM, and Oldstone MB. Virus-specific CD8<sup>+</sup> cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. *J Virol* 1994;68:6103–6110.
- Borrow P, Lewicki H, Wei X, *et al.* Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. *Nat Med* 1997;3:205–211.
- Buseyne F, Fevrier M, Garcia S, Gougeon ML, and Riviere Y. Dual function of a human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte clone: inhibition of HIV replication by noncytolytic mechanisms and lysis of HIV-infected CD4<sup>+</sup> cells. *Virology* 1996;225:248–253.
- Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. *Science* 1995;267:483–489.
- Day CL, Kaufmann DE, Kiepiela P, *et al.* PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. *Nature* 2006;443:350–354.
- De La Cruz J, Vollbrecht T, Frohnen P, *et al.* Ineffectual Targeting of HIV-1 Nef by cytotoxic T lymphocytes in acute infection results in no functional impairment or viremia reduction. *J Virol* 2014;88:7881–7892.
- Goonetilleke N, Liu MK, Salazar-Gonzalez JF, *et al.* The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. *J Exp Med* 2009;206:1253–1272.
- Henn MR, Boutwell CL, Charlebois P, *et al.* Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. *PLoS Pathog* 2012;8:e1002529.
- Ibarrondo FJ, Anton PA, Fuerst M, *et al.* Parallel human immunodeficiency virus type 1-specific CD8<sup>+</sup> T-lymphocyte responses in blood and mucosa during chronic infection. *J Virol* 2005;79:4289–4297.
- Jin X, Bauer DE, Tuttleton SE, *et al.* Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. *J Exp Med* 1999;189:991–998.
- Jones NA, Wei X, Flower DR, *et al.* Determinants of human immunodeficiency virus type 1 escape from the primary CD8<sup>+</sup> cytotoxic T lymphocyte response. *J Exp Med* 2004;200:1243–1256.
- Kalams SA, Buchbinder SP, Rosenberg ES, *et al.* Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. *J Virol* 1999;73:6715–6720.
- Kemball CC, Pack CD, Guay HM, *et al.* The antiviral CD8<sup>+</sup> T cell response is differentially dependent on CD4<sup>+</sup> T cell help over the course of persistent infection. *J Immunol* 2007;179:1113–1121.
- Kiepiela P, Ngumbela K, Thobakgale C, *et al.* CD8<sup>+</sup> T-cell responses to different HIV proteins have discordant associations with viral load. *Nat Med* 2007;13:46–53.
- Klenerman P, and Zinkernagel RM. Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes. *Nature* 1998;394:482–485.
- Koup RA, Safrit JT, Cao Y, *et al.* Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. *J Virol* 1994;68:4650–4655.
- Liu MK, Hawkins N, Ritchie AJ, *et al.* Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. *J Clin Invest* 2013;123:380–393.
- Liu Y, McNevin J, Cao J, *et al.* Selection on the human immunodeficiency virus type 1 proteome following primary infection. *J Virol* 2006;80:9519–9529.
- Martinez-Picado J, Prado JG, Fry EE, *et al.* Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. *J Virol* 2006;80:3617–3623.
- Matloubian M, Concepcion RJ, and Ahmed R. CD4<sup>+</sup> T cells are required to sustain CD8<sup>+</sup> cytotoxic T-cell responses during chronic viral infection. *J Virol* 1994;68:8056–8063.

26. McMichael AJ, and Phillips RE. Escape of human immunodeficiency virus from immune control. *Ann Rev Immunol* 1997;15:271–296.
27. Mellors JW, Rinaldo CR, Jr., Gupta P, White RM, Todd JA, and Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. *Science* 1996; 272:1167–1170.
28. Ndhlovu ZM, Kanya P, Mewalal N, *et al.* Magnitude and kinetics of CD8+ T cell activation during Hyperacute HIV infection impact viral set point. *Immunity* 2015;43:591–604.
29. Parker KC, Bednarek MA, and Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. *J Immunol* 1994;152:163–175.
30. Phillips RE, Rowland-Jones S, Nixon DF, *et al.* Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. *Nature* 1991;354:453–459.
31. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, and Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. *Immunogenetics* 1999;50:213–219.
32. Rosenberg ES. Vigorous HIV-1-Specific CD4+ T cell responses associated with control of viremia. *Science* 1997; 278:1447–1450.
33. Schmitz JE, Kuroda MJ, Santra S, *et al.* Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. *Science* 1999;283:857–860.
34. Schwartz O, Marechal V, Le Gall S, Lemonnier F, and Heard JM. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. *Nat Med* 1996;2:338–342.
35. Streeck H, Jolin JS, Qi Y, *et al.* Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells. *J Virol* 2009;83:7641–7648.
36. Streeck H, and Nixon DF. T cell immunity in acute HIV-1 infection. *J Infect Dis* 2010;202 Suppl 2:S302–S308.
37. Sun Y, Permar SR, Buzby AP, and Letvin NL. Memory CD4+ T-lymphocyte loss and dysfunction during primary simian immunodeficiency virus infection. *J Virol* 2007;81: 8009–8015.
38. van Deutekom HW, Wijnker G, and de Boer RJ. The rate of immune escape vanishes when multiple immune responses control an HIV infection. *J Immunol* 2013;191: 3277–3286.
39. Wong JT, and Colvin RB. Bi-specific monoclonal antibodies: selective binding and complement fixation to cells that express two different surface antigens. *J Immunol* 1987;139:1369–1374.
40. Yang OO, Church J, Kitchen CM, *et al.* Genetic and stochastic influences on the interaction of human immunodeficiency virus type 1 and cytotoxic T lymphocytes in identical twins. *J Virol* 2005;79:15368–15375.
41. Yang OO, Kalams SA, Trocha A, *et al.* Suppression of human immunodeficiency virus type 1 replication by CD8+ cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. *J Virol* 1997;71: 3120–3128.
42. Yang OO, Sarkis PT, Ali A, *et al.* Determinant of HIV-1 mutational escape from cytotoxic T lymphocytes. *J Exp Med* 2003;197:1365–1375.

Address correspondence to:

*Dr. Joseph Kim*

*Division of Infectious Diseases*

*Department of Medicine*

*David Geffen School of Medicine at UCLA*

*10833 Le Conte Ave (Room 37-121CHS)*

*Los Angeles, CA 90095-1688*

*E-mail: jykim81@uic.edu*